India to Launch First Approved Dengue Vaccine Qdenga in 2027
Takeda Pharmaceutical and Dr. Reddy’s Laboratories have signed an agreement to distribute the Qdenga dengue vaccine in India starting in early 2027. The vaccine is approved for individuals aged 4-60 and will initially be available through the private market.
Why it matters
This marks the introduction of India's first approved dengue vaccine, addressing a significant public health challenge in the region.
Takeda’s dengue vaccine Qdenga is expected to be available in India in the first half of 2027. Dr Reddy’s Laboratories and Takeda Pharmaceutical Company announced on Friday (September 18, 2026) the signing of a distribution agreement under which Dr Reddy’s will promote and distribute the vaccine across India’s private market for pediatric and adult vaccination. “Subject to the completion of applicable processes with local authorities, the vaccine is anticipated to become available in the first half of 2027,” the companies stated.
Qdenga is India’s first approved dengue vaccine, and in July 2026, it received marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) for individuals aged 4-60 years.
While inclusion in India’s public immunisation programme remains an important long-term ambition, private market availability through Dr Reddy’s will provide a pathway for eligible individuals to access the vaccine once it becomes available, Takeda said.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in